LGD-3303 — Safety, Research, Risks & Legal Status

Not medical advice. LGD-3303 is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	LGD3303, Ligandrol 3303
Category	SARM
selectivity_ratio	Muscle to prostate approximately 10:1 in animal tissue
development_stage	Terminated preclinical; never advanced to investigational new drug application
US legal status	Not FDA-approved for human use. Sold as a research chemical only. No legitimate pharmaceutical product. WADA-banned.

What is LGD-3303?

Selective androgen receptor modulator (SARM) derived from Ligandrol (LGD-4033) research. Synthetic nonsteroidal agonist targeting androgen receptors. Designed for preclinical efficacy and safety profile exploration.

How it works

Binds androgen receptor with approximately 10-fold selectivity for muscle over prostate tissue in preclinical models. Activation promotes anabolic gene expression and protein synthesis.

Background & history

Developed as analog of Ligandrol (LGD-4033) by academic researchers investigating tissue-selective androgenic effects. Never entered human clinical trials; research terminated.

What the research says

Very limited human evidence. Preclinical and early animal work only. No published human trials. Animal studies report anabolic effects on lean body mass and bone mineral density. Expected to suppress testosterone similar to other SARMs.

Reported effects

Reported anabolic effects in animal muscle models
Studied for potential lean mass preservation
Preclinical research on bone density
Expected strong androgen receptor activity
Suppression of endogenous testosterone likely

Dosing & administration (informational)

Preclinical studies employed dose ranges of variable magnitude to assess pharmacodynamic and toxicological endpoints. No human pharmacokinetic data exists.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

No human safety database; high uncertainty
Testosterone suppression and testicular atrophy expected
Liver function impact unknown in humans
WADA-banned; sport-prohibited substance
Unverified sourcing and purity; significant contamination risk
Experimental compound; self-use carries unknown long-term risks

Drug & supplement interactions

Expected additive suppression with other androgens or SARMs
Unknown effects on hepatic enzyme induction or inhibition
May alter sex hormone-binding globulin dynamics
Potential synergism with estrogen modulation compounds

Who should avoid it

Concurrent use with anabolic steroids, testosterone, or other SARMs
In individuals with compromised hepatic or renal function
In those with existing testicular dysfunction or hypogonadism
During organized sport or drug-tested competition

How it is commonly combined

No human evidence supports any multi-compound regimen; combination use exponentially increases toxicological uncertainty.

Legal & regulatory. Not FDA-approved for human use. Sold as a research chemical only. No legitimate pharmaceutical product. WADA-banned.

Quality & harm reduction

D
e
m
a
n
d
t
h
i
r
d
-
p
a
r
t
y
C
O
A
f
r
o
m
a
n
a
l
y
t
i
c
a
l
l
a
b
v
e
r
i
f
y
i
n
g
c
o
m
p
o
u
n
d
i
d
e
n
t
i
t
y
a
n
d
p
u
r
i
t
y
.
C
h
e
c
k
f
o
r
h
e
a
v
y
m
e
t
a
l
a
n
d
m
i
c
r
o
b
i
a
l
c
o
n
t
a
m
i
n
a
t
i
o
n
;
n
o
G
M
P
a
s
s
u
r
a
n
c
e
t
y
p
i
c
a
l
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

What is LGD-3303?

A research SARM derived from earlier Ligandrol research. Not approved for human use; only available as a 'research chemical' from unregulated suppliers.

Has it been tested in humans?

No published human trials exist. All evidence is preclinical or animal-based.

Why would someone use it?

Anecdotal interest in anabolic effects, but this is experimentally unvalidated and risky.

What are the real risks?

Testosterone suppression, unknown organ effects, unverified product quality, legal risk, and long-term safety unknown.

How different is it from LGD-4033?

Structurally similar but distinct pharmacodynamic profile; both are unproven in humans.

References & further reading

WADA Prohibited List classification
FDA position on nonsteroidal androgen receptor ligands
PubMed preclinical pharmacology of LGD-3303 tissue selectivity